IMMUNOCORE HLDGS ADS/1 (6YG) — Net Asset Quality Index
IMMUNOCORE HLDGS ADS/1 (6YG) has a Net Asset Quality Index of 37.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €1.12 Billion minus total liabilities of €699.62 Million yields net assets of €419.80 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read IMMUNOCORE HLDGS ADS/1 (6YG) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
IMMUNOCORE HLDGS ADS/1 Net Asset Quality Index Over Time (2022–2025)
This chart shows how IMMUNOCORE HLDGS ADS/1's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the index stands at 37.5%, representing net assets of €419.80 Million against total assets of €1.12 Billion EUR. For live market cap and overall valuation, see IMMUNOCORE HLDGS ADS/1 stock valuation.
Annual Net Asset Quality Index for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for IMMUNOCORE HLDGS ADS/1 from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check IMMUNOCORE HLDGS ADS/1 strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 35.7% | €381.03 Million | €1.07 Billion | €686.24 Million | ▼ 0.0 pp |
| 2024 | 35.7% | €360.72 Million | €1.01 Billion | €648.79 Million | ▼ -26.1 pp |
| 2023 | 61.8% | €368.84 Million | €597.00 Million | €228.16 Million | ▼ -2.6 pp |
| 2022 | 64.3% | €338.90 Million | €526.76 Million | €187.86 Million | — |